Literature DB >> 24306269

Association between TNF-α promoter -308 A/G polymorphism and rheumatoid arthritis: a meta-analysis.

Gwan Gyu Song1, Sang-Cheol Bae, Jae-Hoon Kim, Young Ho Lee.   

Abstract

The aim of this study was to determine whether the tumor necrosis factor-α (TNF-α) promoter -308 A/G polymorphism is associated with susceptibility to rheumatoid arthritis (RA) in populations with different ethnicities. MEDLINE and EMBASE databases and manual search were used to identify articles in which TNF-α polymorphism was determined in RA patients and controls. A meta-analysis was conducted on the associations between the TNF-α -308 A/G polymorphism and RA by using (1) allelic contrast and (2) dominant models. A total of 19 studies involving 2,584 RA patients and 3,254 controls were considered. The meta-analysis showed no association between the TNF-α -308 A allele and RA when all the subjects were considered [odds ratio (OR) = 1.129, 95 % CI 0.843-1.513, P = 0.416]. After stratification by ethnicity, the meta-analysis indicated that the A allele was significantly associated with RA in Latin Americans (OR = 1.620, 95 % CI 1.234-2.111, P = 3.6 × 10(-5)), but not in the European, Arab, or Asian populations. The meta-analysis of the AA/AG genotype showed the same pattern of results as with the A allele. No association was noted between the AA/AG genotype and RA when all the subjects were considered (OR = 1.114, 95 % CI 0.812-1.529, P = 0.503), but stratification by ethnicity revealed that the AA/AG genotype was significantly associated with RA in Latin Americans (OR = 1.650, 95 % CI 1.234-2.104, P = 0.001). This meta-analysis showed that the TNF-α -308 A/G polymorphism may represent a significant risk factor for RA in Latin Americans but not in the European, Arab, or Asian populations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24306269     DOI: 10.1007/s00296-013-2919-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  43 in total

Review 1.  Polymorphism of the human TNF-alpha promoter--random variation or functional diversity?

Authors:  R D Allen
Journal:  Mol Immunol       Date:  1999 Oct-Nov       Impact factor: 4.407

2.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

Review 3.  Rheumatoid arthritis. Pathophysiology and implications for therapy.

Authors:  E D Harris
Journal:  N Engl J Med       Date:  1990-05-03       Impact factor: 91.245

4.  Genome scan meta-analysis of rheumatoid arthritis.

Authors:  S J Choi; Y H Rho; J D Ji; G G Song; Y H Lee
Journal:  Rheumatology (Oxford)       Date:  2005-11-08       Impact factor: 7.580

5.  TNF-alpha promoter single nucleotide polymorphisms are markers of human ancestry.

Authors:  A Baena; J Y Leung; A D Sullivan; I Landires; N Vasquez-Luna; J Quiñones-Berrocal; P A Fraser; G P Uko; J C Delgado; O P Clavijo; S Thim; S R Meshnick; T Nyirenda; E J Yunis; A E Goldfeld
Journal:  Genes Immun       Date:  2002-12       Impact factor: 2.676

6.  Tumour necrosis factor a -308 promoter polymorphism in patients with rheumatoid arthritis.

Authors:  Zahra Rezaieyazdi; Jalil Tavakol Afshari; Mahnaz Sandooghi; Farnaz Mohajer
Journal:  Rheumatol Int       Date:  2007-08-29       Impact factor: 2.631

7.  Tumor necrosis factor-alpha and interleukin-10 gene promoter polymorphisms in Turkish rheumatoid arthritis patients.

Authors:  Omer Ates; Gulen Hatemi; Vedat Hamuryudan; Aysegul Topal-Sarikaya
Journal:  Clin Rheumatol       Date:  2008-04-22       Impact factor: 2.980

8.  Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation.

Authors:  A G Wilson; J A Symons; T L McDowell; H O McDevitt; G W Duff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

9.  Inflammatory cytokine responses in juvenile chronic arthritis.

Authors:  M Rooney; J David; J Symons; F Di Giovine; H Varsani; P Woo
Journal:  Br J Rheumatol       Date:  1995-05

10.  Polymorphisms in genes controlling inflammation and tissue repair in rheumatoid arthritis: a case control study.

Authors:  Marieke Emonts; Mieke J M W Hazes; Jeanine J Houwing-Duistermaat; Christa E van der Gaast-de Jongh; Lisette de Vogel; Huub K H Han; Jacques M G W Wouters; Jon D Laman; Radboud J E M Dolhain
Journal:  BMC Med Genet       Date:  2011-03-07       Impact factor: 2.103

View more
  5 in total

1.  Tumor necrosis factor (TNF) and TNFR1 polymorphisms are not risk factors for rheumatoid arthritis in a Mexican population.

Authors:  Daniel Cadena-Sandoval; Isidro Alemán-Ávila; Rosa Elda Barbosa-Cobos; Lizbeth Teresa Becerril-Mendoza; José Manuel Fragoso; Julián Ramírez-Bello
Journal:  Mol Biol Rep       Date:  2018-02-05       Impact factor: 2.316

2.  The -308 TNFα and the -174 IL-6 promoter polymorphisms associate with effective anti-TNFα treatment in seronegative spondyloarthritis.

Authors:  M Fabris; L Quartuccio; C Fabro; S Sacco; S Lombardi; R Ramonda; D Biasi; D Punzi; S Adami; I Olivieri; F Curcio; S De Vita
Journal:  Pharmacogenomics J       Date:  2015-07-07       Impact factor: 3.550

3.  Tumor necrosis factor-α -308 polymorphism in North Indian rheumatoid arthritis patients and association with mRNA and serum TNF-α.

Authors:  Mohd Jahid; Puja Kumari Jha; Diwesh Chawla; Rajnish Avasthi; Rafat Sultana Ahmed
Journal:  Clin Rheumatol       Date:  2017-07-27       Impact factor: 2.980

Review 4.  Circulating interleukin-6 and rheumatoid arthritis: A Mendelian randomization meta-analysis.

Authors:  Bing Li; Yu Xiao; Dan Xing; Xin-Long Ma; Jun Liu
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

5.  Tumor Necrosis Factor Alpha -308G/A Gene Polymorphisms Combined with Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio Predicts the Efficacy and Safety of Anti-TNF-α Therapy in Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Arthritis.

Authors:  Ziran Wang; Lingjun Kong; Han Zhang; Fengchun Sun; Zijian Guo; Rui Zhang; Yaling Dou
Journal:  Front Pharmacol       Date:  2022-01-21       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.